Alkermes Emerges In 2024 With A Fresh Focus
CEO Richard Pops Says The Company Is Returning To Its CNS Routes
As a streamlined pharma business focused on neuroscience, having spun out its oncology programs, Alkermes is building its CNS presence and going “all in” with an early stage pipeline candidate for narcolepsy.
